Immune checkpoint inhibitors in the treatment of oesophageal squamous cell carcinoma: where are we and where are we going?

被引：4
|
作者：
Chen, Ning [2 ,3 ]
Xu, Xiaoling [1 ]
Fan, Yun [1 ]
机构：
[1] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med, Dept Med Thorac Oncol, 1 East Banshan Rd, Hangzhou 310022, Zhejiang, Peoples R China
[2] Zhejiang Chinese Med Univ, Clin Med Coll 2, Dept Oncol, Hangzhou, Zhejiang, Peoples R China
[3] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med, Dept Med Thorac Oncol, Hangzhou, Zhejiang, Peoples R China
来源：
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2023年 / 15卷
基金：
中国国家自然科学基金;
关键词：
biomarker; immune checkpoint inhibitor; immunotherapy; oesophageal squamous cell carcinoma; PD-L1; OPEN-LABEL; TUMOR MICROENVIRONMENT; POOR-PROGNOSIS; PHASE-II; CANCER; NIVOLUMAB; CHEMORADIOTHERAPY; CHEMOTHERAPY; CAMRELIZUMAB; EXPRESSION;
D O I：
10.1177/17588359231189420
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Oesophageal squamous cell carcinoma (ESCC) is a kind of malignant tumour with high invasiveness and a poor prognosis. Immunotherapy, especially immune checkpoint inhibitors (ICIs), is a rapidly growing therapeutic method that activates and enhances anti-tumour immunity to treat patients with malignancy. Several clinical trials have confirmed the efficacy of ICIs in the treatment of ESCC. ICIs have been approved for the treatment of patients with ESCC. However, only a subset of patients can obtain excellent benefits from ICI therapy. In recent years, there has been a growing interest in exploring predictive biomarkers of immunotherapy response. In this review, we highlighted the predictive biomarkers for the prognosis of ESCC patients treated with ICIs and pointed out the existing problems and the direction of future research in this field.
引用
收藏
页数：18
相关论文
共 50 条
  • [31] VSP - WHERE WE ARE, WHERE WE ARE GOING
    HARDAGE, BA
    OIL & GAS JOURNAL, 1988, 86 (12) : 91 - 93
  • [32] AIDS - WHERE ARE WE AND WHERE ARE WE GOING
    GATELL, JM
    MEDICINA CLINICA, 1992, 98 (20): : 775 - 777
  • [33] WHERE ARE WE NOW AND WHERE ARE WE GOING
    KARLAN, BY
    GYNECOLOGIC ONCOLOGY, 1995, 59 (03) : 315 - 317
  • [34] Pharmacologic treatment of GERD: Where we are now, and where are we going?
    Scarpignato, Carmelo
    Hongo, Michio
    Wu, Justin C. Y.
    Lottrup, Christian
    Lazarescu, Adriana
    Stein, Ellen
    Hunt, Richard H.
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 2020, 1482 (01) : 193 - 212
  • [35] WHERE WE ARE AND WHERE WE ARE GOING - DISCUSSION
    WOOD, PHN
    JOURNAL OF RHEUMATOLOGY, 1983, 10 : 115 - 117
  • [36] Sarcopenia: Where are we and where are we going?
    Studenski, Stephanie
    AUSTRALASIAN JOURNAL ON AGEING, 2017, 36 : 14 - 14
  • [37] Microfinance: where are we and where are we going?
    Nogueira, Serafim
    Duarte, Fabio
    Gama, Ana Paula
    DEVELOPMENT IN PRACTICE, 2020, 30 (07) : 874 - 889
  • [38] Where Are We Now and Where Are We Going?
    Sempokuya, Tomoki
    McDonald, Nicholas
    ACG CASE REPORTS JOURNAL, 2023, 10 (05)
  • [39] Endometriosis: where are we and where are we going?
    Greene, Alexis D.
    Lang, Stephanie A.
    Kendziorski, Jessica A.
    Sroga-Rios, Julie M.
    Herzog, Thomas J.
    Burns, Katherine A.
    REPRODUCTION, 2016, 152 (03) : R63 - R78
  • [40] RPC: where we are and where we are going
    Santonico, R
    NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION A-ACCELERATORS SPECTROMETERS DETECTORS AND ASSOCIATED EQUIPMENT, 2000, 456 (1-2): : 1 - 5
12345